Nexalin Technology reports secondary analysis improvements in Alzheimer’s trial data
Nexalin Technology said further ADAS-Cog data analysis from its randomized, sham-controlled trial found improvements tied to memory domains in Alzheimer’s patients. The Company plans to use ADAS-Cog subscale results for a planned U.S. Alzheimer’s pilot study.
Further analysis of ADAS-Cog data from the Company’s randomized, sham-controlled clinical trial — previously published in the Journal of Alzheimer’s Disease and in Radiology — identifies specific improvements in cognitive domains associated with memory in Alzheimer’s patientsOne half of evaluable a…